Clinical Trials Browser

Phase 3 × Recruiting × ensartinib × Clear all

NCT05341583 2024-08-23

Ensartinib as Adjuvant Treatment in Anaplastic Lymphoma Kinase (ALK) Positive Non-small Cell Lung Cancer

Phase 3 Recruiting

Carcinoma, Non-Small-Cell Lung